Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

775.85 -5.75 (-0.74%)

Streaming Delayed Price Updated: 3:14 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

60 61 Next >

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss

September 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

Examining the Quality Attributes of NASDAQ:REGN. ↗

September 22, 2023

Why the quality investor may take a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN).

Via Chartmill

Analyst Expectations for Regeneron Pharmaceuticals's Future ↗

September 21, 2023

Via Benzinga

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/19 Morning Trading

September 19, 2023

Via Investor Brand Network

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

September 18, 2023

Via Benzinga

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost ↗

September 20, 2023

A higher-dose version of Eylea will help the company fight off competition and increase revenue.

Via The Motley Fool

3 Stocks to Buy to Ride Europe’s Coming Market Surge ↗

September 19, 2023

With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023 ↗

September 15, 2023

Via Benzinga

Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗

September 14, 2023

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

September 08, 2023

Via Benzinga

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 9/8 Morning Trading

September 08, 2023

Via Investor Brand Network

AI Integration In Biotech & Pharma: Companies Positioned To Benefit ↗

September 11, 2023

The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....

Via Benzinga

Topics Artificial Intelligence

New to Investing? Here's How You Can Get Started With $500. ↗

September 10, 2023

You don't have to invest a lot to start building a winning portfolio.

Via The Motley Fool

3 Unstoppable Growth Stocks to Buy Right Now ↗

September 09, 2023

These healthcare stocks show no signs of slowing down.

Via The Motley Fool

Regeneron Provides Update on Planned Chief Financial Officer Transition

September 08, 2023

Robert E. Landry to retire effective February 2024; Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,000 Today ↗

September 05, 2023

Via Benzinga

Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity ↗

August 30, 2023

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

August 25, 2023

Via Benzinga

Regeneron Announces Updates to Board of Directors

September 08, 2023

Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron’s Board of Directors

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Top Biotech Stocks to Buy in September ↗

September 08, 2023

There is rarely a bad time to buy stocks with massive upside potential.

Via The Motley Fool

Could This Biosimilar Drug Be Novartis' Next Blockbuster? ↗

September 05, 2023

Novartis expects to submit regulatory applications for its biosimilar soon.

Via The Motley Fool

Is REGENERON PHARMACEUTICALS (NASDAQ:REGN) suited for quality investing? ↗

September 01, 2023

This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)

Via Chartmill

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc. (Nasdaq - ACER), Sovos Brands, Inc. (Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq -

August 31, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Is Regeneron Stock a Buy Now? ↗

August 25, 2023

The company's growth fuel isn't running out yet.

Via The Motley Fool

Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy ↗

August 29, 2023

Celularity Inc (NASDAQ: CELU) shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc (NASDAQ: REGN).

Via Benzinga

Wall Street Thinks This Tiny Biotech Company Could Soar Soon ↗

August 28, 2023

An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.

Via The Motley Fool

These Are the ONLY 7 Penny Stocks to Consider in August 2023 ↗

August 26, 2023

These are just a few of the most promising penny stocks to consider as we head into the final months of the year.

Via InvestorPlace

Regeneron Announces Investor Conference Presentations

August 23, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.